Sodium phenylbutyrate - Acer Therapeutics
Alternative Names: ACER 001; OLPRUVALatest Information Update: 28 Aug 2024
At a glance
- Originator Baylor College of Medicine
- Developer Acer Therapeutics; RELIEF THERAPEUTICS Holding
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Ammonia scavengers; Histone deacetylase inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inborn urea cycle disorders
- No development reported Maple syrup urine disease